Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 6, 2012, Pages 906-913

  Zittema, Debbie ^a   Boertien, Wendy E ^a   van Beek, André P ^a   Dullaart, Robin P F ^a   Franssen, Casper F M ^a   de Jong, Paul E ^a   Meijer, Esther ^a   Gansevoort, Ron T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COPEPTIN; DESMOPRESSIN; VASOPRESSIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUID BALANCE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CONCENTRATING CAPACITY; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; MALE; PLASMA OSMOLALITY; URINE OSMOLALITY; WATER DEPRIVATION;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DEAMINO ARGININE VASOPRESSIN; DISEASE PROGRESSION; FEMALE; GLYCOPEPTIDES; HUMANS; KIDNEY; KIDNEY CONCENTRATING ABILITY; MALE; MIDDLE AGED; NETHERLANDS; NEUROPHYSINS; OSMOLAR CONCENTRATION; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROTEIN PRECURSORS; REGRESSION ANALYSIS; TIME FACTORS; VASOPRESSINS; WATER DEPRIVATION; WATER-ELECTROLYTE BALANCE; YOUNG ADULT;

EID: 84862194446     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.11311111     Document Type: Article

References (39)

1. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301, 2007
2. Chabardès D, Imbert-Teboul M, Elalouf JM: Functional properties of Ca2+-inhibitable type 5 and type 6 adenylyl cyclases and role of Ca2+ increase in the inhibition of intracellular cAMP content. Cell Signal 11: 651-663, 1999
3. Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ: Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 30: 703-709, 1997
4. Gattone VH 2nd, Maser RL, Tian C, Rosenberg JM, Branden MG: Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet 24: 309-318, 1999
5. Hanaoka K, Guggino WB: cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 11: 1179-1187, 2000
6. Torres VE: Vasopressin antagonists in polycystic kidney disease. Semin Nephrol 28: 306-317, 2008
7. Meijer E, Gansevoort RT, de Jong PE, van derWal AM, Leonhard WN, de Krey SR, van den Born J, Mulder GM, van Goor H, Struck J, de Heer E, Peters DJ: Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease:Optimal timing and dosing of the drug. Nephrol Dial Transplant 26: 2445-2453, 2011
8. Gattone VH 2nd, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-1326, 2003
9. Wang X, Gattone V 2nd, Harris PC, Torres VE: Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16: 846-851, 2005
10. Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS: Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3-4 study. Am J Kidney Dis 57: 692-699, 2011
11. Meijer E, Rook M, Tent H, Navis G, van der Jagt EJ, de Jong PE, Gansevoort RT: Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 5: 1091-1098, 2010
12. Seeman T, Dusek J, Vondrák K, Bláhová K, Simková E, Kreisinger J, Dvorák P, Kyncl M, Hríbal Z, Janda J: Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 53: 629-634, 2004
13. Kääriäinen H, Koskimies O, Norio R: Dominant and recessive polycystic kidney disease in children: Evaluation of clinical features and laboratory data. Pediatr Nephrol 2: 296-302, 1988
14. Fick GM, Duley IT, Johnson AM, Strain JD, Manco-Johnson ML, Gabow PA: The spectrum of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol 4: 1654-1660, 1994
15. Gabow PA, Kaehny WD, Johnson AM, Duley IT, Manco-Johnson M, Lezotte DC, Schrier RW: The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int 35: 675-680, 1989
16. Wilson PD, Schrier RW, Breckon RD, Gabow PA: A new method for studying human polycystic kidney disease epithelia in culture. Kidney Int 30: 371-378, 1986
17. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM: Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 343: 824-827, 1994
18. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139: 137-147, 2003
19. Miller M, Dalakos T, Moses AM, Fellerman H, Streeten DH: Recognition of partial defects in antidiuretic hormone secretion. Ann Intern Med 73: 721-729, 1970
20. Fenske W, Quinkler M, Lorenz D, Zopf K, Haagen U, Papassotiriou J, Pfeiffer AF, Fassnacht M, Störk S, Allolio B: Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome-revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab 96: 1506-1515, 2011
21. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
22. Martinez-Maldonado M, Yium JJ, Eknoyan G, Suki WN: Adult polycystic kidney disease: Studies of the defect in urine concentration. Kidney Int 2: 107-113, 1972
23. D'Angelo A, Mioni G, Ossi E, Lupo A, Valvo E, Maschio G: Alterations in renal tubular sodium and water transport in polycystic kidney disease. Clin Nephrol 3: 99-105, 1975
24. Argent NB, Burrell LM, Goodship TH, Wilkinson R, Baylis PH: Osmoregulation of thirst and vasopressin release in severe chronic renal failure. Kidney Int 39: 295-300, 1991
25. Danielsen H, Pedersen EB, Nielsen AH, Herlevsen P, Kornerup HJ, Posborg V: Expansion of extracellular volume in early polycystic kidney disease. Acta Med Scand 219: 399-405, 1986
26. Michalski A, Grzeszczak W: [The effect of hypervolemia on electrolyte level and level of volume regulating hormones in patients with autosomal dominant polycystic kidney disease]. Pol Arch Med Wewn 96: 329-343, 1996
27. Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB: Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 5: I129-I138, 1983
28. Baumann G, Dingman JF: Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest 57: 1109-1116, 1976
29. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52: 112-119, 2006
30. Morgenthaler NG, Struck J, Jochberger S, Dünser MW: Copeptin: Clinical use of a new biomarker. Trends Endocrinol Metab 19: 43-49, 2008
31. Meijer E, Bakker SJ, de Jong PE, Homan van der Heide JJ, van Son WJ, Struck J, Lems SP, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 88: 561-567, 2009
32. Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 77: 29-36, 2010
33. Meijer E, Bakker SJ, van der Jagt EJ, Navis G, de Jong PE, Struck J, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6: 361-368, 2011
34. Yasuda G, Jeffries WB: Regulation of cAMP production in initial and terminal innermedullary collecting ducts. Kidney Int 54: 80-86, 1998
35. Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, Nagao S, Rome LA, Sullivan LP, Grantham JJ: cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57: 1460-1471, 2000
36. Li CH, Hsieh SM, Nagai I: The response of plasma arginine vasopressin to 14 h water deprivation in the elderly. Acta Endocrinol (Copenh) 105: 314-317, 1984
37. Tryding N, Berg B, Ekman S, Nilsson JE, Sterner G, Harris A: DDAVP test for renal concentration capacity. Age-related reference intervals. Scand J Urol Nephrol 22: 141-145, 1988
38. Perucca J, Bouby N, Valeix P, Bankir L: Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am J Physiol Regul Integr Comp Physiol 292: R700-R705, 2007
39. Baldwin DS, Berman HJ, Heinemann HO, Smith HW: The elaboration of osmotically concentrated urine in renal disease. J Clin Invest 34: 800-807, 1955.